Mental health is one of the defining challenges of our time, and the human, social, and economic costs are profound.
Conventional treatments help many, but their efficacy is often limited, side effects can be severe, and countless people continue to live with debilitating conditions that do not respond to existing approaches.
For too many, the consequences are tragic — including suicide and debilitating conditions that current systems cannot adequately address.
Psychedelic‑assisted therapies are emerging as one of the most promising areas in contemporary mental‑health research.
Clinical trials show meaningful potential in treating PTSD, addiction, major depression, anxiety disorders, OCD, eating disorders, and treatment‑resistant depression.
This work points to more than new medicines: it signals a deeper shift in how healing is understood — woven into biology, psychology, context, and lived experience.
Our Work
We are a Community Interest Company dedicated to funding independent psychedelic research and increasing public understanding of these emerging treatments.
Through community involvement, education, and public engagement, we aim to empower people with accurate, evidence‑based knowledge about psychedelic therapies and their potential role in mental‑health care.
In the short term, we are supporting research through the Maria Sabina Fund — an award for PhD candidates conducting groundbreaking psychedelic studies at UK universities. We fund this work through community events, crowdfunding initiatives, and grassroots philanthropy.
In the longer term, we endeavour to create a sustainable, community‑driven philanthropic engine for psychedelic research that will support independent science, expand public understanding, and help shape a new chapter in mental‑health treatments.
Together, we can help transform the future of mental health and wellness — guided by evidence, strengthened by community, and grounded in the possibility of genuine healing.
